UZH-Logo

Maintenance Infos

Browse by Creators - Zurich Open Repository and Archive

Navigate back| Up a level
Export as
Number of items: 4.

Zoufaly, A; Jochum, J; Hammerl, R; Nassimi, N; Raymond, Y; Burchard, G D; Schmiedel, S; Drexler, J F; Campbell, N K; Taka, N; Awasom, C; Metzner, K J; van Lunzen, J; Feldt, T (2015). Virological failure after 1 year of first-line ART is not associated with HIV minority drug resistance in rural Cameroon. Journal of Antimicrobial Chemotherapy, 70(3):922-925.

Metzner, K J; Rauch, P; Braun, P; Knechten, H; Ehret, R; Korn, K; Kaiser, R; Sichtig, N; Ranneberg, B; van Lunzen, J; Walter, H (2011). Prevalence of key resistance mutations K65R, K103N, and M184V as minority HIV-1 variants in chronically HIV-1 infected, treatment-naïve patients. Journal of Clinical Virology, 50(2):156-161.

Reekie, J; Mocroft, A; Ledergerber, B; Beniowski, M; Clotet, B; van Lunzen, J; Chiesi, A; Pradier, C; Machala, L; Lundgren, J D (2010). History of viral suppression on combination antiretroviral therapy as a predictor of virological failure after a treatment change. HIV Medicine, 11(7):469-478.

Wyen, C; Hendra, H; Vogel, M; Hoffmann, C; Knechten, H; Brockmeyer, N H; Bogner, J R; Rockstroh, J; Esser, S; Jaeger, H; Harrer, T; Mauss, S; van Lunzen, J; Skoetz, N; Jetter, A; Groneuer, C; Fätkenheuer, G; Khoo, S H; Egan, D; Back, D J; Owen, A (2008). Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. Journal of Antimicrobial Chemotherapy, 61(4):914-918.

This list was generated on Tue Jul 25 11:53:57 2017 CEST.